Perturbations of the Gut Microbiome and Metabolome in Children with Calcium Oxalate Kidney Stone DiseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether the gut microbiome and its metabolic output relate to early-onset calcium oxalate kidney stone disease in children. The link between gut microbial communities and pediatric stone formation was previously unknown. Investigators ran a case-control study using shotgun metagenomic sequencing and untargeted metabolomics on stool. They compared microbial composition, functional genes, and fecal metabolites between stone formers and matched controls.
Who was studied?
The cohort was 88 individuals aged 4 to 18 years. It included 44 children with kidney stones containing at least 50% calcium oxalate and 44 controls matched for age, sex, and race. All participants were human pediatric and adolescent subjects. Samples were stool specimens. The matched design controlled for demographic differences between the stone and control groups.
What were the most important findings?
Children who formed stones had a significantly less diverse gut microbiome than controls. Among taxa with prevalence above 0.1%, 31 taxa were less abundant in the stone formers. These included seven taxa that produce butyrate and three taxa that degrade oxalate. The depletion was mirrored by decreased abundance of the gene encoding butyryl-coA dehydrogenase (p = 0.02). The abundance of these bacteria correlated with 18 fecal metabolites, whose levels differed between groups. Microbial diversity varied with age of stone onset and was lowest in those who first formed stones at age 9 to 14 years, while controls showed no age-related diversity differences.
What are the greatest implications of this study?
The results suggest that loss of gut bacteria that produce butyrate and degrade oxalate, together with the linked metabolome shifts, may be upstream determinants of early-onset calcium oxalate stone disease. This reframes stones as partly a gut microbial and metabolic condition. The design is a case-control comparison, so it identifies associations rather than proving that microbial loss causes stones. The cohort was limited to 88 children at a single pediatric setting, so broader validation is needed before informing prevention.